Arnaud D Kaze1, Solomon K Musani2, Aurelian Bidulescu3, Joshua J Joseph4, Adolfo Correa2, Chiadi E Ndumele5, Alain G Bertoni6, Rexford S Ahima2, Sherita H Golden7,8, Justin B Echouffo-Tcheugui7,8. 1. Department of Medicine, University of Maryland Medical Center, Baltimore, MD, USA. 2. Department of Medicine, University of Mississippi Medical Center, Jackson, USA. 3. Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA. 4. Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Ohio State University, Columbus, OH, USA. 5. Department of Medicine, Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, MD, USA. 6. Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA. 7. Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Johns Hopkins School of Medicine, Baltimore, MD, USA. 8. Welch Prevention Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore, MD, USA.
Abstract
AIM: To evaluate the association between plasma biomarkers including leptin, adiponectin, adiponectin-to-leptin ratio and high-sensitivity C-reactive protein (hsCRP) with risk of glycaemic progression and incident dysglycaemia (pre-diabetes or diabetes) in a community-based sample of African American (AAs). METHODS: We analysed data from 3223 participants without type 2 diabetes at baseline (2000-2004) who attended ≥1 follow-up visit. Poisson regression was used to generate risk ratios (RRs) for glycaemic progression and incident dysglycaemia. RESULTS: Over a median of 7 years, 46.4% developed glycaemic progression (n=1495). After adjusting for demographic and lifestyle variables, the RRs (95% CI) for glycaemic progression comparing highest (Q4) to lowest (Q1) quartiles were 1.30 (1.10-1.54), 0.74 (0.65-0.84), 0.70 (0.62-0.80) and 1.22 (1.07-1.38) for leptin, adiponectin, adiponectin-leptin ratio and hsCRP, respectively. Upon additional adjustment for BMI, the corresponding RRs (95% CIs) were 1.15 (0.94-1.42), 0.76 (0.67-0.86), 0.72 (0.62-0.84) and 1.14 (0.99-1.31) respectively. Among participants with normal glycaemia, the RRs (95% CIs) for incident pre-diabetes in Q4 vs Q1 were 1.37 (1.13-1.67), 0.73 (0.63-0.85), 0.70 (0.59-0.82) and 1.28 (1.10-1.48) for leptin, adiponectin, adiponectin-leptin ratio and hsCRP, respectively; equivalent RRs for incident diabetes were 5.15 (2.63-10.10), 0.36 (0.20-0.68), 0.21 (0.12-0.38) and 3.04 (1.70-5.44), respectively. CONCLUSIONS: In this large community-based cohort of AAs, our results suggest that high plasma leptin and hsCRP, as well as low adiponectin and adiponectin-to-leptin ratio, are associated with higher risks of glycaemic progression. The findings point to the potential utility of these biomarkers in predicting and preventing glycaemic progression in this high-risk population.
AIM: To evaluate the association between plasma biomarkers including leptin, adiponectin, adiponectin-to-leptin ratio and high-sensitivity C-reactive protein (hsCRP) with risk of glycaemic progression and incident dysglycaemia (pre-diabetes or diabetes) in a community-based sample of African American (AAs). METHODS: We analysed data from 3223 participants without type 2 diabetes at baseline (2000-2004) who attended ≥1 follow-up visit. Poisson regression was used to generate risk ratios (RRs) for glycaemic progression and incident dysglycaemia. RESULTS: Over a median of 7 years, 46.4% developed glycaemic progression (n=1495). After adjusting for demographic and lifestyle variables, the RRs (95% CI) for glycaemic progression comparing highest (Q4) to lowest (Q1) quartiles were 1.30 (1.10-1.54), 0.74 (0.65-0.84), 0.70 (0.62-0.80) and 1.22 (1.07-1.38) for leptin, adiponectin, adiponectin-leptin ratio and hsCRP, respectively. Upon additional adjustment for BMI, the corresponding RRs (95% CIs) were 1.15 (0.94-1.42), 0.76 (0.67-0.86), 0.72 (0.62-0.84) and 1.14 (0.99-1.31) respectively. Among participants with normal glycaemia, the RRs (95% CIs) for incident pre-diabetes in Q4 vs Q1 were 1.37 (1.13-1.67), 0.73 (0.63-0.85), 0.70 (0.59-0.82) and 1.28 (1.10-1.48) for leptin, adiponectin, adiponectin-leptin ratio and hsCRP, respectively; equivalent RRs for incident diabetes were 5.15 (2.63-10.10), 0.36 (0.20-0.68), 0.21 (0.12-0.38) and 3.04 (1.70-5.44), respectively. CONCLUSIONS: In this large community-based cohort of AAs, our results suggest that high plasma leptin and hsCRP, as well as low adiponectin and adiponectin-to-leptin ratio, are associated with higher risks of glycaemic progression. The findings point to the potential utility of these biomarkers in predicting and preventing glycaemic progression in this high-risk population.
Authors: Ervin R Fox; Emelia J Benjamin; Daniel F Sarpong; Charles N Rotimi; James G Wilson; Michael W Steffes; Guanjie Chen; Adebowale Adeyemo; Jason K Taylor; Tandaw E Samdarshi; Herman A Taylor Journal: Am J Cardiol Date: 2008-07-25 Impact factor: 2.778
Authors: Katherine M Flegal; Deanna Kruszon-Moran; Margaret D Carroll; Cheryl D Fryar; Cynthia L Ogden Journal: JAMA Date: 2016-06-07 Impact factor: 56.272
Authors: Marieke B Snijder; Robert J Heine; Jacob C Seidell; Lex M Bouter; Coen D A Stehouwer; Giel Nijpels; Tohru Funahashi; Yuji Matsuzawa; Iichiro Shimomura; Jacqueline M Dekker Journal: Diabetes Care Date: 2006-11 Impact factor: 19.112
Authors: Russell A Miller; Qingwei Chu; John Le Lay; Philipp E Scherer; Rexford S Ahima; Klaus H Kaestner; Marc Foretz; Benoit Viollet; Morris J Birnbaum Journal: J Clin Invest Date: 2011-05-23 Impact factor: 14.808
Authors: Aurelian Bidulescu; Jiankang Liu; Solomon K Musani; Ervin R Fox; Tandaw E Samdarshi; Daniel F Sarpong; Viola Vaccarino; Peter W Wilson; Donna K Arnett; Rebecca Din-Dzietham; Herman A Taylor; Gary H Gibbons Journal: Circ Heart Fail Date: 2011-08-12 Impact factor: 8.790
Authors: Jiankang Liu; Kenneth R Butler; Sarah G Buxbaum; Jung Hye Sung; Brenda W Campbell; Herman A Taylor Journal: Clin Endocrinol (Oxf) Date: 2009-05-16 Impact factor: 3.478